86. Pulmonary arterial hypertension Clinical trials / Disease details

Clinical trials : 1,205 / Drugs : 684 - (DrugBank : 124) / Drug target genes : 100 - Drug target pathways : 193

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03950739 (ClinicalTrials.gov)	September 17, 2019	9/5/2019	Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso	An Open-label, Clinical Study to Evaluate the Safety and Tolerability of Treprostinil Inhalation Powder (TreT) in Subjects With Pulmonary Arterial Hypertension Currently Using Tyvaso	Pulmonary Arterial Hypertension	Drug: Treprostinil Inhalation Powder	United Therapeutics	NULL	Active, not recruiting	18 Years	N/A	All	51	Phase 1	United States
2	NCT03464864 (ClinicalTrials.gov)	March 9, 2018	1/3/2018	Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder in Healthy Normal Volunteers	A Phase 1, Single-center, Open-label, Dose-Rising Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder (TrIP) in Healthy Normal Volunteers	Pulmonary Arterial Hypertension	Drug: Treprostinil Inhalation Powder	Mannkind Corporation	NULL	Completed	18 Years	55 Years	All	36	Phase 1	United States